Trial Profile
A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya (Fingolimod)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms ToFingo Successor
- 03 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials database .
- 02 Jul 2014 New trial record